. 2021 Dec 27;24(6):1157–1167. doi: 10.1007/s12094-021-02756-w

Table 3.

PBMC phenotypes, inflammation and associations with DMFS

	n	HR (95% CI)	p
CD3⁺CD4⁺	32	1.003 (0.939–1.071)	0.938
CD3⁺CD4⁺LAG-3⁺	32	< 0.001 (< 0.001–0.378)	0.032
CD3⁺CD4⁺CD127^lo/−CD25^hi	32	1.000 (0.997–1.004)	0.793
CD3⁺CD8⁺	32	0.987 (0.902–1.080)	0.779
CD3⁺CD8⁺CXCR4⁺	32	0.915 (0.857–0.978)	0.009
IgD⁺CD27⁻	32	0.960 (0.914–1.007)	0.096
CD20⁺CD27⁺	32	1.045 (0.988–1.106)	0.127
CD33⁺CD11b⁺CD14⁺	32	1.000 (1.000–1.000)	0.023
IL-6	42	1.460 (1.069–1.993)	0.017
IFN-γ	25	1.000 (0.999–1.001)	0.868

HR below 1 indicates favourable DMFS with higher PBMC population count or lower serum cytokine value, from Cox proportional hazard models; patients’ cytokine values were normalised to the mean value of each analysis assay batch for use in the model

CI confidence interval, DMFS distant metastasis-free survival, HR hazard ratio, IFN interferon, IL interleukin, LAG lymphocyte activation gene, PBMC peripheral blood mononuclear cell